ReviewBriefings in bioinformatics2024
Exploring the potential of large language model-based chatbots in challenges of ribosome profiling data analysis: a review.
Review in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ribosome profiling (Ribo-seq) provides transcriptome-wide insights into protein synthesis dynamics, yet its analysis poses challenges, particularly for nonbioinformatics researchers. Large language model-based chatbots offer promising solutions by leveraging natural language processing. This review explores their convergence, highlighting opportunities for synergy. We discuss challenges in Ribo-seq analysis and how chatbots mitigate them, facilitating scientific discovery. Through case studies, we illustrate chatbots' potential contributions, including data analysis and result interpretation. Despite the absence of applied examples, existing software underscores the value of chatbots and the large language model. We anticipate their pivotal role in future Ribo-seq analysis, overcoming limitations. Challenges such as model bias and data privacy require attention, but emerging trends offer promise. The integration of large language models and Ribo-seq analysis holds immense potential for advancing translational regulation and gene expression understanding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.